Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 326

1.

Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry.

Vogel B, Chandrasekhar J, Baber U, Mastoris I, Sartori S, Aquino M, Krucoff MW, Moliterno DJ, Henry TD, Weisz G, Gibson CM, Iakovou I, Kini AS, Farhan S, Sorrentino S, Faggioni M, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen DJ, Stuckey T, Ariti C, Dangas GD, Pocock S, Mehran R.

Thromb Haemost. 2019 Jul 31. doi: 10.1055/s-0039-1693463. [Epub ahead of print]

PMID:
31365942
2.

Dual Antiplatelet Therapy: Is It Time to Cut the Cord With Aspirin?

Ziada KM, Moliterno DJ.

JAMA. 2019 Jun 25;321(24):2409-2411. doi: 10.1001/jama.2019.7025. No abstract available.

PMID:
31237621
3.

Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention.

Sibbing D, Aradi D, Alexopoulos D, Ten Berg J, Bhatt DL, Bonello L, Collet JP, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong YH, Mehran R, Moliterno DJ, Neumann FJ, Pereira NL, Price MJ, Sabatine MS, So DYF, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ.

JACC Cardiovasc Interv. 2019 Aug 26;12(16):1521-1537. doi: 10.1016/j.jcin.2019.03.034. Epub 2019 Jun 12. Review.

PMID:
31202949
4.

Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry.

Joyce LC, Baber U, Claessen BE, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Ariti C, Dangas G, Faggioni M, Aoi S, Gibson CM, Aquino M, Krucoff MW, Vogel B, Moliterno DJ, Sorrentino S, Colombo A, Chieffo A, Kini A, Guedeney P, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R.

JACC Cardiovasc Interv. 2019 May 27;12(10):983-992. doi: 10.1016/j.jcin.2019.02.033.

PMID:
31122354
5.

Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.

Faggioni M, Baber U, Sartori S, Chandrasekhar J, Cohen DJ, Henry TD, Claessen BE, Dangas GD, Gibson CM, Krucoff MW, Vogel B, Moliterno DJ, Sorrentino S, Colombo A, Chieffo A, Kini A, Farhan S, Ariti C, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R.

Circ Cardiovasc Interv. 2019 Apr;12(4):e007133. doi: 10.1161/CIRCINTERVENTIONS.118.007133.

PMID:
30998384
6.

Mitral Regurgitation and Evolving Transcatheter Treatments: Insights From the JACC Family of Journals.

Moliterno DJ, Windecker S; JACC: Cardiovascular Interventions Editors.

J Am Coll Cardiol. 2019 Mar 26;73(11):1353-1357. doi: 10.1016/j.jacc.2019.02.011. No abstract available.

PMID:
30898211
7.

Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention.

Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP.

Circulation. 2018 Jul 31;138(5):527-536. doi: 10.1161/CIRCULATIONAHA.118.034722. Review.

PMID:
30571525
8.

Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial.

Ungar L, Clare RM, Rodriguez F, Kolls BJ, Armstrong PW, Aylward P, Held C, Moliterno DJ, Strony J, Van de Werf F, Wallentin L, White HD, Tricoci P, Harrington RA, Mahaffey KW, Melloni C.

J Am Heart Assoc. 2018 Dec 18;7(24):e009609. doi: 10.1161/JAHA.118.009609.

9.

Being a Great Reviewer: Remembering the "Why".

Moliterno DJ.

JACC Cardiovasc Interv. 2018 Oct 22;11(20):2130-2131. doi: 10.1016/j.jcin.2018.09.011. No abstract available.

PMID:
30336820
10.

Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry).

Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD, Farhan S, Sharma M, Ariti C, Dangas G, Gibson M, Faggioni M, Krucoff MW, Aquino M, Chandrasekhar J, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R.

Am J Cardiol. 2018 Nov 15;122(10):1638-1646. doi: 10.1016/j.amjcard.2018.07.041. Epub 2018 Aug 20.

PMID:
30270177
11.

Year 1: A Short Look Back and a Long Look Forward.

Moliterno DJ.

JACC Cardiovasc Interv. 2018 Sep 10;11(17):1793-1795. doi: 10.1016/j.jcin.2018.08.001. No abstract available.

12.

Effects of genetic variation in protease activated receptor 4 after an acute coronary syndrome: Analysis from the TRACER trial.

Tricoci P, Neely M, Whitley MJ, Edelstein LC, Simon LM, Shaw C, Fortina P, Moliterno DJ, Armstrong PW, Aylward P, White H, Van de Werf F, Jennings LK, Wallentin L, Held C, Harrington RA, Mahaffey KW, Bray PF.

Blood Cells Mol Dis. 2018 Sep;72:37-43. doi: 10.1016/j.bcmd.2018.07.004. Epub 2018 Jul 21.

13.

Discharge timing and outcomes after uncomplicated non-ST-segment elevation acute myocardial infarction.

Rymer JA, Tempelhof MW, Clare RM, Pieper KS, Granger CB, Van de Werf F, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Lopes RD, Mahaffey KW, Newby LK.

Am Heart J. 2018 Jul;201:103-110. doi: 10.1016/j.ahj.2018.04.010. Epub 2018 Apr 20.

14.

Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).

Baber U, Li SX, Pinnelas R, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ, Colombo A, Mehran R.

Circ Cardiovasc Interv. 2018 Mar;11(3):e006144. doi: 10.1161/CIRCINTERVENTIONS.117.006144.

PMID:
29870385
15.

Images in Intervention: Icons.

Moliterno DJ.

JACC Cardiovasc Interv. 2018 May 28;11(10):1018-1019. doi: 10.1016/j.jcin.2018.04.023. No abstract available.

16.

Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention.

Tricoci P, Newby LK, Clare RM, Leonardi S, Gibson CM, Giugliano RP, Armstrong PW, Van de Werf F, Montalescot G, Moliterno DJ, Held C, Aylward PE, Wallentin L, Harrington RA, Braunwald E, Mahaffey KW, White HD.

JACC Cardiovasc Interv. 2018 May 14;11(9):856-864. doi: 10.1016/j.jcin.2018.02.006.

17.

State-of-the-Art Papers: Gemstones.

Moliterno DJ.

JACC Cardiovasc Interv. 2018 Mar 26;11(6):613-614. doi: 10.1016/j.jcin.2018.02.016. No abstract available.

18.

The Top Papers of 2017: Editor's Pick.

Moliterno DJ.

JACC Cardiovasc Interv. 2018 Mar 12;11(5):513-515. doi: 10.1016/j.jcin.2018.02.001. No abstract available.

19.

Clinical features and outcomes of patients with type 2 myocardial infarction: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.

Guimarães PO, Leonardi S, Huang Z, Wallentin L, de Werf FV, Aylward PE, Held C, Harrington RA, Moliterno DJ, Armstrong PW, White HD, Alexander KP, Lopes RD, Mahaffey KW, Tricoci P.

Am Heart J. 2018 Feb;196:28-35. doi: 10.1016/j.ahj.2017.10.007. Epub 2017 Oct 16.

PMID:
29421012
20.

The Top Papers of 2017: By Subsequent Citations and Online Views and Downloads.

Moliterno DJ.

JACC Cardiovasc Interv. 2018 Feb 12;11(3):325-327. doi: 10.1016/j.jcin.2018.01.228. No abstract available.

21.

Hybrid coronary revascularization: Time for a new comparator?

Misumida N, Moliterno DJ.

Catheter Cardiovasc Interv. 2018 Feb 1;91(2):213-214. doi: 10.1002/ccd.27503.

PMID:
29405596
22.

The Year of Special Anniversaries: Tin, Crystal, Silver, and Ruby.

Moliterno DJ.

JACC Cardiovasc Interv. 2017 Dec 26;10(24):2587-2588. doi: 10.1016/j.jcin.2017.11.010. No abstract available.

23.

Research Correspondence: One Good Point, One Great Figure (or Table).

Moliterno DJ.

JACC Cardiovasc Interv. 2017 Nov 27;10(22):2347-2348. doi: 10.1016/j.jcin.2017.10.017. No abstract available.

24.

CTO-Chronic Total Occlusions and Continuous Training Opportunity.

Moliterno DJ.

JACC Cardiovasc Interv. 2017 Nov 13;10(21):2231-2232. doi: 10.1016/j.jcin.2017.10.001. No abstract available.

25.

One Man's Vacation, Another Man's Stress Test.

Moliterno DJ.

JACC Cardiovasc Interv. 2017 Oct 23;10(20):2133-2134. doi: 10.1016/j.jcin.2017.09.007. No abstract available.

26.

White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry).

Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ, Colombo A, Mehran R.

Circ Cardiovasc Interv. 2017 Sep;10(9). pii: e004981. doi: 10.1161/CIRCINTERVENTIONS.117.004981.

27.

Little Kids, Little Problems-Big Kids, Big Problems.

Moliterno DJ.

JACC Cardiovasc Interv. 2017 Sep 11;10(17):1807-1808. doi: 10.1016/j.jcin.2017.08.002. No abstract available.

28.

Be Careful What You Read and the Company You Keep.

Moliterno DJ.

JACC Cardiovasc Interv. 2017 Aug 28;10(16):1715-1716. doi: 10.1016/j.jcin.2017.07.024. No abstract available.

29.

The Value of Focus.

Moliterno DJ.

JACC Cardiovasc Interv. 2017 Aug 14;10(15):1603-1604. doi: 10.1016/j.jcin.2017.07.003. No abstract available.

30.

JACC: Cardiovascular Interventions 2.0: The Journey Begins.

Moliterno DJ.

JACC Cardiovasc Interv. 2017 Jul 24;10(14):1473-1474. doi: 10.1016/j.jcin.2017.06.016. No abstract available.

31.

A Letter to the (Founding) Editor: A King by Any Name.

Moliterno DJ.

JACC Cardiovasc Interv. 2017 Jul 10;10(13):1378-1379. doi: 10.1016/j.jcin.2017.05.043. No abstract available.

32.

Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites.

Koshizaka M, Lopes RD, Newby LK, Clare RM, Schulte PJ, Tricoci P, Mahaffey KW, Ogawa H, Moliterno DJ, Giugliano RP, Huber K, James S, Harrington RA, Alexander JH.

Am J Med. 2017 Oct;130(10):1170-1176. doi: 10.1016/j.amjmed.2017.03.030. Epub 2017 Apr 8.

PMID:
28396226
33.

Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.

Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, Armstrong PW, White HD, Held C, Aylward PE, Van de Werf F, Harrington RA, Mahaffey KW, Tricoci P.

Eur Heart J. 2017 Mar 14;38(11):804-810. doi: 10.1093/eurheartj/ehw525.

34.

Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry.

Faggioni M, Baber U, Sartori S, Giustino G, Cohen DJ, Henry TD, Farhan S, Ariti C, Dangas G, Gibson M, Giacoppo D, Krucoff MW, Aquino M, Chandrasekhar J, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R.

JACC Cardiovasc Interv. 2017 Apr 10;10(7):645-654. doi: 10.1016/j.jcin.2016.12.003. Epub 2017 Mar 15.

35.

More Time to SORT OUT Clinical Outcomes After First-Generation Drug-Eluting Stents: Related Versus Unrelated Events.

Moliterno DJ, Ziada KM.

J Am Coll Cardiol. 2017 Feb 14;69(6):625-627. doi: 10.1016/j.jacc.2016.11.054. No abstract available.

36.

Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.

Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay JF, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP.

Circ Cardiovasc Interv. 2016 Nov;9(11). pii: e004395. Review.

PMID:
27803042
37.

Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.

Armaganijan LV, Alexander KP, Huang Z, Tricoci P, Held C, Van de Werf F, Armstrong PW, Aylward PE, White HD, Moliterno DJ, Wallentin L, Chen E, Harrington RA, Strony J, Mahaffey KW, Lopes RD.

Am Heart J. 2016 Aug;178:176-84. doi: 10.1016/j.ahj.2016.05.012. Epub 2016 Jun 9.

PMID:
27502866
38.

Albuminuria and cardiovascular events in patients with acute coronary syndromes: Results from the TRACER trial.

Åkerblom A, Clare RM, Lokhnygina Y, Wallentin L, Held C, Van de Werf F, Moliterno DJ, Patel UD, Leonardi S, Armstrong PW, Harrington RA, White HD, Aylward PE, Mahaffey KW, Tricoci P.

Am Heart J. 2016 Aug;178:1-8. doi: 10.1016/j.ahj.2016.04.013. Epub 2016 Apr 27.

PMID:
27502846
39.

Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents.

Yu J, Baber U, Mastoris I, Dangas G, Sartori S, Steg PG, Cohen DJ, Giustino G, Chandrasekhar J, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, Moliterno DJ, Colombo A, Pocock S, Mehran R.

JACC Cardiovasc Interv. 2016 Jul 25;9(14):1461-9. doi: 10.1016/j.jcin.2016.04.004.

40.

Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome.

Hess PL, Wojdyla DM, Al-Khatib SM, Lokhnygina Y, Wallentin L, Armstrong PW, Roe MT, Ohman EM, Harrington RA, Alexander JH, White HD, Van de Werf F, Piccini JP, Held C, Aylward PE, Moliterno DJ, Mahaffey KW, Tricoci P.

JAMA Cardiol. 2016 Apr 1;1(1):73-9. doi: 10.1001/jamacardio.2015.0359.

PMID:
27437658
41.

Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry.

Baber U, Dangas G, Chandrasekhar J, Sartori S, Steg PG, Cohen DJ, Giustino G, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, Moliterno DJ, Weisz G, Colombo A, Pocock S, Mehran R.

JACC Cardiovasc Interv. 2016 Jul 11;9(13):1349-57. doi: 10.1016/j.jcin.2016.04.009.

42.

Lack of Concordance Between Local Investigators, Angiographic Core Laboratory, and Clinical Event Committee in the Assessment of Stent Thrombosis: Results From the TRACER Angiographic Substudy.

Popma CJ, Sheng S, Korjian S, Daaboul Y, Chi G, Tricoci P, Huang Z, Moliterno DJ, White HD, Van de Werf F, Harrington RA, Wallentin L, Held C, Armstrong PW, Aylward PE, Strony J, Mahaffey KW, Gibson CM.

Circ Cardiovasc Interv. 2016 May;9(5):e003114. doi: 10.1161/CIRCINTERVENTIONS.115.003114.

PMID:
27162212
43.

Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial.

Vranckx P, White HD, Huang Z, Mahaffey KW, Armstrong PW, Van de Werf F, Moliterno DJ, Wallentin L, Held C, Aylward PE, Cornel JH, Bode C, Huber K, Nicolau JC, Ruzyllo W, Harrington RA, Tricoci P.

J Am Coll Cardiol. 2016 May 10;67(18):2135-2144. doi: 10.1016/j.jacc.2016.02.056.

44.

Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.

Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S.

J Am Coll Cardiol. 2016 May 17;67(19):2224-2234. doi: 10.1016/j.jacc.2016.02.064. Epub 2016 Apr 11.

45.

Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.

Harskamp RE, Clare RM, Ambrosio G, Held C, Lokhnygina Y, Moliterno DJ, White HD, Aylward PE, Armstrong PW, Mahaffey KW, Harrington RA, Van de Werf F, Wallentin L, Strony J, Tricoci P.

Eur Heart J Acute Cardiovasc Care. 2017 Mar;6(2):155-163. doi: 10.1177/2048872616633880. Epub 2016 Sep 20.

PMID:
26895973
46.

Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.

Déry JP, Mahaffey KW, Tricoci P, White HD, Podder M, Westerhout CM, Moliterno DJ, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Armstrong PW, Rao SV.

Catheter Cardiovasc Interv. 2016 Aug;88(2):163-73. doi: 10.1002/ccd.26335. Epub 2015 Dec 23.

PMID:
26698636
47.

Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery.

van Diepen S, Tricoci P, Podder M, Westerhout CM, Aylward PE, Held C, Van de Werf F, Strony J, Wallentin L, Moliterno DJ, White HD, Mahaffey KW, Harrington RA, Armstrong PW.

J Am Heart Assoc. 2015 Dec 15;4(12). pii: e002546. doi: 10.1161/JAHA.115.002546.

48.

Ageless benefits of transradial access for percutaneous coronary revascularization.

Kim SM, Moliterno DJ.

Catheter Cardiovasc Interv. 2015 Nov 15;86(6):973-4. doi: 10.1002/ccd.26305. No abstract available.

PMID:
26541798
49.

Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.

Ziada KM, Abdel-Latif AK, Charnigo R, Moliterno DJ.

Catheter Cardiovasc Interv. 2016 Mar;87(4):722-732. doi: 10.1002/ccd.26110. Epub 2015 Aug 26. Review.

50.

Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years.

Kragholm K, Halim SA, Yang Q, Schulte PJ, Hochman JS, Melloni C, Mahaffey KW, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Ohman EM, Van de Werf F, Tricoci P, Alexander JH, Giugliano RP, Newby LK.

Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):357-67. doi: 10.1161/CIRCOUTCOMES.114.001615. Epub 2015 Jul 7.

Supplemental Content

Loading ...
Support Center